Tenax Therapeutics, Inc. (TENX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenax Therapeutics, Inc. on April 22, 2026. The filing discloses the appointment of a new Chief Financial Officer (CFO) and the resignation of the Interim CFO. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol "TENX."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes and Executive Compensation
The primary material change is the appointment of Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026. Concurrently, Thomas A. McGauley resigned as Interim CFO, effective May 10, 2026, though he will continue consulting services through the filing of the Q1 2026 Form 10-Q.
Key terms of Mr. Staab's employment agreement include:
- Base Salary: $428,000 annually.
- Target Bonus: 45% of base salary.
- Equity Inducement Awards:
- 10,000 Restricted Stock Units (RSUs): 25% vest 10 days after start; remainder vests in three equal installments over 12 months.
- 450,000 Stock Options: 25% vest on the first anniversary; remainder vests in 36 monthly installments.
- Severance Provisions:
- Standard Termination (without Cause/Good Reason): 9 months base salary, pro-rated bonus, and 9 months COBRA.
- Termination within 1 year of Corporate Transaction: 12 months base salary, full bonus, and 12 months COBRA.
Outlook, Risks, and Contingencies
The filing does not contain specific guidance, outlook, or risk factors beyond the standard disclosure that severance payments are conditioned upon the execution of a release of claims. The equity awards were approved by the Compensation Committee without stockholder approval pursuant to Nasdaq Listing Rules.
Investor Verification Checklist
- Verify the exact vesting schedules and performance conditions for the 450,000 stock options and 10,000 RSUs in the attached Exhibits 10.2 and 10.3.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for definitions of "Cause," "Good Reason," and "Corporate Transaction."
- Confirm the transition timeline for the Interim CFO's consulting role and the filing date of the upcoming Form 10-Q.
- Assess the impact of the new CFO's compensation package on the Company's future cash burn and dilution.